Patients with cirrhosis frequently present with high serum ferritin and low transferrin concentrations, reflecting impaired liver function and inflammation. Recent studies have shown that transferrin and its saturation with iron are Model for End-Stage Liver Disease-independent predictors of mortality in patients with acute-on-chronic liver failure or decompensated cirrhosis. The aim of this study was to evaluate the prognostic utility of serum iron parameters in relation to markers of liver function and immune activation. Clinical, demographic, and biochemical data were retrospectively analyzed from a cohort of 1255 consecutive patients with cirrhosis (age ≥ 18 years) who presented from August 1, 2004 until December 31, 2014 at the University Hospital of Innsbruck. Patients with malignancies at diagnosis including hepatocellular carcinoma were excluded. Survival analysis was carried out by Cox regression by using baseline laboratory parameters, and findings were validated in an independent patient cohort. During a median follow-up of 2.4 years, 193 deaths occurred and 254 patients underwent liver transplantation. In patients with transferrin <180 mg/dL, 3-month, 1-year, and 5-year transplant-free survival estimates were significantly lower (91.7%, 79.0%, and 30.5%) when compared with the group of patients with transferrin ≥ 180 mg/dL (98.9%, 95.5%, and 68.0%, \( P < 0.001 \)). Transferrin predicted transplant-free survival independently of Model for End-Stage Liver Disease–sodium (MELD-Na) and C-reactive protein (CRP) in multivariate regression analysis including all patients. When patients with alcoholic or nonalcoholic fatty liver disease were excluded, transferrin was in addition an albumin-independent predictor of transplant-free survival. In conclusion, the association of transferrin with transplant-free survival is independent of MELD-Na score and CRP. In patients without fatty liver disease, transferrin also predicts survival independently of albumin.

Liver Transplantation 24 343–351 2018 AASLD.
Received August 9, 2017; accepted November 2, 2017.

The Model for End-Stage Liver Disease (MELD) has evolved as a reference staging system for cirrhosis and is used for prognosis, evaluation for liver transplantation, and donor liver allocation.\(^1\)\(^-\)\(^3\) Incorporating sodium, age, or albumin into modified MELD scores improves accuracy in predicting survival in patients with cirrhosis.\(^4\)\(^-\)\(^8\) In search for additional prognostic parameters, high ferritin at the time of listing for liver transplantation was identified as an independent predictor of wait-list mortality,\(^9\) but the prognostic utility of ferritin could not be reproduced in a larger cohort.\(^10\) When transferrin saturation was taken into consideration, ferritin could predict mortality on the waiting list and after orthotopic liver transplantation.\(^11\) Iron overload was therefore proposed as a risk factor for mortality in patients with liver disease. Accordingly, transferrin and transferrin saturation have also been identified as predictors of survival in patients with decompensated cirrhosis and acute-on-chronic liver failure (ACLF).\(^12\)\(^,\)\(^13\) Transferrin is lower in patients with cirrhosis and impaired synthetic function.\(^14\) High ferritin and low transferrin can indicate inflammation,\(^15\)\(^,\)\(^16\) which is also a risk factor for disease progression and mortality in cirrhosis. In addition, alcohol and metabolic factors can directly affect iron metabolism.\(^17\)\(^-\)\(^19\) Hence, it
remains unclear if altered iron metabolism is cause or consequence of advanced liver disease in different etiologies.

The effect of inflammation and hepatic function on serum iron parameters was assessed by correlating serum ferritin, transferrin, and transferrin saturation with C-reactive protein (CRP) and albumin. The prognostic utility of all these parameters was determined by survival analysis in a large cohort of unselected patients with cirrhosis.

Patients and Methods

PATIENT DEMOGRAPHICS AND LABORATORY DATA

Derivation Cohort

From a cohort of consecutive 1437 patients (age ≥ 18 years) with liver cirrhosis who presented from August 1, 2004 to December 31, 2014 at the University Hospital of Innsbruck, 182 patients with hepatocellular carcinoma or other malignancy at diagnosis were excluded, resulting in a final study cohort of 1255 patients (Fig. 1). Diagnosis of cirrhosis was made according to clinical, biochemical, and imaging criteria.\(^{(20)}\) We received ethical approval by the ethics committee of the Medical University of Innsbruck to conduct this study.

Clinical, demographic, and biochemical data were collected by retrospective review of patient charts. MELD score was calculated according to the United Network for Organ Sharing (UNOS) model, in which a MELD score over 11 requires serum sodium correction (Model for End-Stage Liver Disease—sodium [MELD-Na]).\(^{(3,6,7)}\)

The majority of patients (79%; 989 patients) were outpatients. The remaining 266 patients were hospitalized; 65 (5%) of whom were treated in an intermediate care unit. The start date of this cohort corresponds to the first assessment of serum iron parameters, and study end points were death, liver transplantation, or last follow-up. Accordingly, prognosis was calculated using 3-month, 1-year, and 5-year transplant-free survival, in which patients who underwent liver transplantation or were lost to follow-up were right-censored.

Validation Cohort

In order to validate the results of this investigation, a cohort of 596 unselected patients with cirrhosis was included in the 2 study centers: Innsbruck (302 patients) and Vienna (294 patients) from January 1, 2004 to March 31, 2016. Inclusion criteria were identical to those applied to the derivation cohort.

STATISTICAL ANALYSIS

SPSS Statistics, version 22.0.0.1 (IBM Corp., Armonk, NY) and MedCalc, version 17.7.2 (MedCalc Software, Ostend, Belgium) were used for statistical analysis, and a significance value of 0.05 was considered in all statistic tests. Kolmogorov-Smirnov test was used to test normality of distribution. Not normally distributed variables were reanalyzed after logarithmic transformation. Continuous variables were reported by using median and interquartile range and analyzed by using Student \(t\) test or the Mann-Whitney U test, as appropriate. Categorical variables were expressed in frequencies (with percentages in parentheses) and tested for significance using the \(\chi^2\) test or the Fisher’s exact test. Survival models were built based on univariate and multivariate Cox regression analysis. For survival analysis, 3-month, 1-year, and 5-year transplant-free survival rates were analyzed. Receiver operating characteristic (ROC) calculations were performed, and the Youden index was applied to calculate the optimal transferrin cutoff point. Kaplan-Meier analysis was then carried out to determine survival according to transferrin levels and groups were compared using the log-rank test. Correlation analysis for transferrin, CRP, and albumin were carried out using the Spearman’s rank correlation coefficient because all 3 variables did not show a normal distribution.
Results

To determine whether transferrin is a predictor of survival in unselected patients with cirrhosis, clinical and biochemical parameters were retrospectively assessed in a cohort of 1255 cirrhosis patients. During a median follow-up of 2.4 years (95% confidence interval [CI], 0.1-9.0), 193 (15%) deaths occurred, and 254 (20%) patients underwent liver transplantation. For validation, an independent cohort of patients was recruited at the liver centers in Innsbruck and Vienna. Baseline patient characteristics of the derivation and validation cohort are shown in Table 1.

Univariate Cox regression analysis showed that ferritin, transferrin, and transferrin saturation, but not

| TABLE 1. Clinical Characteristics and Outcome of Patients Stratified According to MELD Score |
|-----------------------------------------------|-----------------------------------------------|----------------|
| Derivation Cohort                            | Validation Cohort                             | P Value       |
| (n = 1255)                                    | (n = 596)                                     |               |
| Age, years                                    | 57 (49-64)                                    | 55 (48-63)    | 0.002 |
| Sex, female/male                              | 404/851 (32.2/67.8)                           | 166/430 (27.9/72.1) | 0.06  |
| Underlying liver disease                      |                                              |               |
| ALD                                           | 222 (17.7)                                    | 21 (3.5)      | <0.001|
| NAFLD                                         | 563 (44.9)                                    | 121 (20.3)    |       |
| HBV/HCV                                       | 254 (20.2)                                    | 140 (23.5)    |       |
| Cryptogenic                                   | 80 (6.4)                                      | 5 (0.8)       |       |
| Biliary (PSC/PBC)                             | 26 (2.1)                                      | 66 (11.1)     |       |
| Autoimmune                                    | 23 (1.8)                                      | 94 (15.8)     |       |
| Metabolic (HH/α1-ATD/Wilson’s)                |                                              |               |
| Other                                         | 35 (2.8)                                      | 104 (17.4)    |       |
| White cell count, G/L*                       | 6.0 (4.4-7.8)                                 | —             |       |
| Hemoglobin, g/L*                              | 123 (107-140)                                 | —             |       |
| Platelet count, G/L*                         | 116 (75.8-168)                                | —             |       |
| CRP, mg/dL                                    | 0.60 (0.21-1.42)                              | 0.35 (0.11-1.18) | <0.001|
| Albumin, mg/dL                                | 3530 (2998-4080)                              | 3630 (3093-4082) | 0.07  |
| Creatinine, mg/dL                             | 0.84 (0.68-1.06)                              | 0.84 (0.72-0.10) | 0.94  |
| MELD-No score                                 | 13 (9-18)                                     | 11 (8-17)     | <0.001|
| Bilirubin, mg/dL                              | 1.61 (0.90-3.09)                              | 1.24 (0.78-2.59) | <0.001|
| INR                                           | 1.3 (1.1-1.5)                                 | 1.3 (1.1-1.44) | 0.001 |
| Sodium, mmoVL                                 | 138 (135-140)                                 | 138 (135-140) | 0.53  |
| Serum iron, μmol/L                           | 17.6 (10.3-25.9)                              | 19.8 (11.4-27.8) | 0.006 |
| Serum ferritin, μg/L                          | 204 (70-510)                                  | 215 (68-596)  | 0.18  |
| Transferrin, mg/dL                            | 232 (170-285)                                 | 248 (180-295) | 0.005 |
| Transferrin saturation, %                     | 32 (17-54)                                    | 33 (20-57)    | 0.20  |
| Transplant-free survival rates, % (n)         |                                              |               |
| 3-month                                       | 97.0 (1085/1118)                              | 95.9 (534/557) | 0.25  |
| 1-year                                        | 91.6 (779/850)                                | 86.2 (413/479) | 0.002 |
| 5-year                                        | 58.8 (227/386)                                | 49.5 (147/297) | 0.002 |

NOTE: Data are given as n (%) or median (interquartile range). *n = 1254.
serum iron, were significantly associated with transplant-free survival. Of all serum iron parameters, transferrin is the only independent predictor of survival in the derivation and validation cohort (Table 2).

ROC curve analysis showed that the best cutoff for transferrin to predict 3-month transplant-free survival is 180 mg/dL (Fig. 2). The 3-month, 1-year, and 5-year transplant-free survival estimates were significantly lower in the group of patients with transferrin < 180 mg/dL (91.7%, 79.0%, and 30.5%) when compared with the group of patients with transferrin ≥ 180 mg/dL (98.9%, 95.5%, and 68.0%; Table 4; Fig. 3A). Stratification based on transferrin also showed that patients with transferrin < 180 mg/dL were more likely to be male and have cirrhosis due to alcoholic liver disease (ALD) or nonalcoholic fatty liver disease (NAFLD) as an underlying etiology. Patients with low transferrin also had more advanced liver disease (higher MELD-Na score), higher white cell count, and higher levels of CRP (Table 4).

To test if etiology had an impact on the predictive power of transferrin, we next grouped patients according to underlying disease. This analysis showed that transplant-free survival was not significantly different in the ALD- or NAFLD-associated cirrhosis group when compared with all other etiologies (log-rank \( P = 0.10 \)). Transferrin independently predicted transplant-free survival in the group of patients with cirrhosis caused by diseases other than ALD or NAFLD (hazard ratio [HR], 0.985; 95% CI, 0.985-0.992; \( P < 0.001 \)). Individual subgroup analysis for patients with ALD or NAFLD showed that transferrin was significantly associated with transplant-free survival (ALD—HR, 0.535; 95% CI, 0.318-0.900; \( P = 0.02 \); NAFLD—HR, 0.572; 95% CI, 0.443-0.739; \( P < 0.001 \)), but this association was lost for both subgroups when MELD or MELD-Na was added to a multivariate model (data not shown).

To further study the impact of cirrhosis stage on the utility of transferrin for prognosis, we analyzed patient subgroups with MELD-Na ≥ 15 and patients with MELD-Na < 15, which is the accepted cutoff for transplant evaluation. As shown in Fig. 3B, transplant-free survival was significantly higher in patients with transferrin ≥ 180 mg/dL in the cohort with a MELD-Na score < 15 (\( P < 0.001 \)). In the group of patients with MELD-Na score ≥ 15, this association

| Table 2. Univariate and Multivariate Cox Regression: Serum Iron Parameters |
|------------------|------------------|------------------|------------------|------------------|
|                  | Derivation Cohort (n = 1255) |                  | Validation Cohort (n = 596) |                  |
|                  | Univariate Cox Regression HR (95% CI) | \( P \) Value | Multivariate Cox Regression HR (95% CI) | \( P \) Value |
| Age, years       | 1.023 (1.010-1.036) | <0.001 | 1.026 (1.013-1.040) | <0.001 |
| Serum iron, m\(\mu\)mol/L | 0.995 (0.982-1.008) | 0.47 | — | — |
| Serum ferritin, g/L | 1.038 (1.021-1.054) | <0.001 | 1.008 (0.983-1.035) | 0.54 |
| Transferrin, g/L  | 0.496 (0.411-0.598) | <0.001 | 0.563 (0.419-0.755) | <0.001 |
| Transferrin saturation, % | 1.011 (1.006-1.017) | <0.001 | 1.005 (0.994-1.016) | 0.37 |

FIG. 2. ROC curves: diagnostic accuracy of MELD-Na and transferrin to predict 3-month transplant-free mortality. AUC with 95% CIs are indicated. For means of comparison, transferrin is indicated in opposite test direction compared with MELD-Na.
was lost, showing that transferrin is a better predictor of survival at earlier liver disease stages (Fig. 3C).

Next, the effect of inflammation on transferrin concentration and its association with mortality were assessed using CRP as a surrogate parameter. Figure 4 shows a nonlinear but significantly negative correlation between transferrin and CRP, which confirms that transferrin is a negative acute phase reactant. As shown in Table 3, multivariate Cox regression analysis including all patients showed a stronger prediction of mortality for transferrin than for CRP. These results were confirmed in the validation cohort.

To assess the interactions between hepatic synthetic function and transferrin, albumin was next included in the analysis. Pearson correlation showed a stronger and linear association between transferrin and albumin (Fig. 4B). Multivariate Cox regression analysis including albumin revealed different results for the derivation and validation cohort. In search for factors accounting for these differences, patients were grouped by disease stage (MELD-Na cutoff 15) or by etiology. As shown in Table 5 and in accordance with previous studies,(22) MELD-Na is a poor predictor of survival in patients with early cirrhosis (MELD-Na < 15). In this patient group, albumin remained the only independent predictor of survival in the derivation and validation cohort. When patients with ALD or NAFLD were excluded, on the basis that alcohol and metabolic syndrome directly affect serum iron parameters, transferrin was a predictor of transplant-free survival independently of MELD-Na, CRP, and albumin in both cohorts (Table 6).

**Discussion**

Beyond the immediate implications for predicting outcomes, studying prognostic factors in patients with...
FIG. 4. Correlation analysis: transferrin versus (A) CRP and (B) transferrin versus albumin.

### TABLE 4. Clinical Characteristics and Outcome of Patients Stratified According to Transferrin Concentration

|                      | Derivation Cohort | Validation Cohort |
|----------------------|-------------------|-------------------|
|                      | n = 352           | n = 903           |
|                      | n = 147           | n = 449           |
| **Age, years**       | 56 (48-63)        | 57 (49-64)        |
|                      | (27.3/72.7)       | (34.1/165.9)      |
| **Sex, female/male** | 96/256            | 308/595           |
|                      | (27.3/72.7)       | (34.1/165.9)      |
| **Underlying liver disease** |                 |                  |
| ALD                  | 89 (25.3)         | 5 (3.4)           |
|                      | 133 (14.7)        | 16 (3.6)          |
| NAFLD                | 177 (50.3)        | 31 (21.1)         |
|                      | 386 (42.7)        | 90 (20.0)         |
| HBV/HCV              | 40 (11.4)         | 14 (9.5)          |
|                      | 214 (23.7)        | 126 (28.1)        |
| Cryptogenic          | 20 (5.7)          | 2 (1.4)           |
|                      | 60 (6.6)          | 3 (0.7)           |
| Biliary (PSC/PBC)    | 3 (0.9)           | 14 (9.5)          |
|                      | 49 (5.4)          | 31 (6.9)          |
| Autoimmune           | 4 (1.1)           | 11 (7.5)          |
|                      | 22 (2.4)          | 55 (12.2)         |
| Metabolic (HH/s1-ATD/Wilson) | 10 (2.8) | 37 (25.2) |
|                      | 13 (1.4)          | 57 (12.7)         |
| Other                | 9 (2.6)           | 33 (22.4)         |
|                      | 26 (2.9)          | 71 (15.8)         |
| **White cell count, g/L** | 7.0 (5.1-9.1)*    | 5.6 (4.3-7.2)     |
|                      | (11-144)         | <0.001            |
| **Hemoglobin, g/L**  | 111 (98-124)*     | 128 (113-144)     |
|                      | (3.0-15.5)       | <0.001            |
| **Platelet count, g/L** | 105 (69-150)*    | 118 (77-171)      |
|                      | (3.0-15.5)       | 0.01              |
| **CRP, mg/dL**       | 1.54 (0.86-3.28)  | 0.38 (0.14-0.93)  |
|                      | <0.001           | 1.28 (0.49-2.74)  |
|                      | 0.23 (0.10-0.64)  | <0.001            |
| **Albumin, mg/dL**   | 2950 (2520-3470)  | 3740 (3250-4210)  |
|                      | <0.001           | 3070 (2700-3440)  |
|                      | 3780 (3320-4195)  | <0.001            |
| **Creatinine, mg/dL** | 0.88 (0.66-1.26)  | 0.83 (0.68-1.00)  |
|                      | <0.001           | 0.86 (0.72-1.12)  |
|                      | 0.83 (0.71-0.96)  | 0.04              |
| **MELD-Na score**    | 19 (15-25)        | 12 (9-15)         |
|                      | <0.001           | 19 (15-24)        |
|                      | 10 (8-14)         | <0.001            |
| **Bilirubin, mg/dL** | 3.35 (1.72-6.27)  | 1.27 (0.79-2.21)  |
|                      | <0.001           | 3.30 (1.69-6.82)  |
|                      | 1.04 (0.74-1.79)  | <0.001            |
| **INR**              | 1.5 (1.3-1.7)     | 1.2 (1.1-1.4)     |
|                      | <0.001           | 1.5 (1.3-1.8)     |
|                      | 1.2 (1.1-1.3)     | <0.001            |
| **Sodium, mmol/L**   | 135 (131-138)     | 139 (136-141)     |
|                      | <0.001           | 135 (132-138)     |
|                      | 138 (136-140)     | <0.001            |
| **Serum iron, μmol/L** | 17.1 (10.7-24.6) | 17.7 (10.3-26.3)  |
|                      | 0.21             | 19.8 (11.6-26.9)  |
|                      | 19.8 (11.3-28.1)  | 0.69              |
| **Serum ferritin, μg/L** | 540 (245-1031)  | 141 (48-310)      |
|                      | <0.001           | 660 (286-1344)    |
|                      | 153 (50-420)      | <0.001            |
| **Transferrin, mg/dL** | 136.5 (106-160)  | 261 (226-303)     |
|                      | <0.001           | 136 (103-160)     |
|                      | 272 (234-315)     | <0.001            |
| **Transferrin saturation, %** | 58 (32-84) | 27 (15-42) |
|                      | <0.001           | 65 (36-88)        |
|                      | 28 (17-44)       | <0.001            |
| **Transplant-free survival rate, % (n)** |                 |                  |
| 3-month              | 91.7 (265/289)    | 98.9 (820/829)    |
|                      | <0.001           | 83.5 (106/127)    |
|                      | 99.5 (482/430)    | <0.001            |
| 1-year               | 79.0 (158/200)    | 95.5 (621/650)    |
|                      | <0.001           | 62.6 (62/99)      |
|                      | 92.4 (351/380)    | <0.001            |
| 5-year               | 30.5 (29/95)      | 68.0 (198/291)    |
|                      | <0.001           | 20.5 (15/73)      |
|                      | 58.9 (132/224)    | <0.001            |

NOTE: Data are given as n (%) or median (interquartile range).

*n = 351.
TABLE 5. Univariate and Multivariate Cox Regression: Iron, Inflammation, and Hepatic Function at Different Cirrhosis Stages

|                  | Derivation Cohort | Validation Cohort |
|------------------|------------------|------------------|
|                  | Univariate Cox   | Multivariate Cox | Univariate Cox   | Multivariate Cox |
|                  | Regression HR    | Regression HR    | Regression HR    | Regression HR    |
|                  | (95% CI)         | (95% CI)         | (95% CI)         | (95% CI)         |
| HR (95% CI)      | P Value          | HR (95% CI)      | P Value          | HR (95% CI)      | P Value          |

Model A: all patients

| Age, years       | 1.023  | <0.001 | 1.035  | <0.001 | 1.047  | <0.001 | 1.042  | <0.001 |
| MELD-Na score    | 1.122  | <0.001 | 1.096  | <0.001 | 1.084  | <0.001 | 1.047  | <0.001 |
| CRP, mg/dL       | 1.127  | <0.001 | 1.020  | 0.53   | 1.088  | <0.001 | 1.022  | 0.41   |
| Albumin, g/L     | 0.921  | <0.001 | 0.949  | <0.001 | 0.914  | <0.001 | 0.955  | 0.001  |
| Transferrin, g/L | 0.496  | <0.001 | 0.917  | 0.47   | 0.498  | <0.001 | 0.750  | 0.02   |

Model B: MELD-Na < 15

| Age, years       | 1.024  | 0.009  | 1.022  | 0.02   | 1.044  | <0.001 | 1.041  | <0.001 |
| MELD-Na score    | 1.144  | 0.001  | 1.075  | 0.10   | 1.153  | <0.001 | 1.071  | 0.10   |
| CRP, mg/dL       | 1.164  | 0.001  | 1.060  | 0.32   | 1.105  | 0.003  | 1.071  | 0.09   |
| Albumin, g/L     | 0.925  | <0.001 | 0.952  | 0.005  | 0.900  | <0.001 | 0.913  | <0.001 |
| Transferrin, g/L | 0.473  | <0.001 | 0.689  | 0.04   | 0.613  | 0.001  | 0.842  | 0.29   |

Model C: MELD-Na ≥ 15

| Age, years       | 1.031  | 0.001  | 1.044  | <0.001 | 1.043  | 0.001  | 1.045  | <0.001 |
| MELD-Na score    | 1.155  | <0.001 | 1.155  | <0.001 | 1.053  | 0.009  | 1.049  | 0.02   |
| CRP, mg/dL       | 1.055  | 0.10   | —      | —      | 1.035  | 0.25   | —      | —      |
| Albumin, g/L     | 0.944  | <0.001 | 0.944  | 0.001  | 0.985  | 0.43   | —      | —      |
| Transferrin, g/L | 0.701  | 0.01   | 1.032  | 0.85   | 0.649  | 0.007  | 0.663  | 0.02   |

Cirrhosis helps improve our understanding of disease pathogenesis and could ultimately lead to the identification of new therapeutic targets. Recent studies have shown that serum iron parameters are independent predictors of survival in patients awaiting liver transplantation, ACLF, and critically ill patients.\(^{11-13,23}\)

TABLE 6. Univariate and Multivariate Cox Regression: Iron, Inflammation, and Hepatic Function in Patients Without Fatty Liver Disease (ALD or NAFLD)

|                  | Derivation Cohort (n = 454) | Validation Cohort (n = 470) |
|------------------|-----------------------------|-----------------------------|
|                  | Univariate Cox Regression   | Multivariate Cox Regression | Univariate Cox Regression | Multivariate Cox Regression |
|                  | HR (95% CI)                 | HR (95% CI)                 | HR (95% CI)                 | HR (95% CI)                 |
|                  | P Value                     | P Value                     | P Value                     | P Value                     |

| Age, years       | 1.029  | 0.003  | 1.031  | 0.001  | 1.045  | <0.001 | 1.040  | 0.000  |
| MELD-Na score    | 1.142  | <0.001 | 1.106  | 0.000  | 1.082  | <0.001 | 1.037  | 0.014  |
| CRP, mg/dL       | 1.175  | <0.001 | 0.996  | 0.940  | 1.085  | <0.001 | 1.022  | 0.469  |
| Albumin, g/L     | 0.898  | <0.001 | 0.928  | 0.000  | 0.911  | <0.001 | 0.963  | 0.022  |
| Transferrin, g/L | 0.311  | <0.001 | 0.613  | 0.029  | 0.406  | <0.001 | 0.582  | 0.000  |
A main finding of this study is that of all serum iron parameters, transferrin is the best prognostic parameter and it is independent of MELD-Na. In contrast to the ACLF cohort, where the best cutoff for transferrin was 87 mg/dL, the best predictive power of transferrin in our cohort for a 3-month and 1-year survival was 180 mg/dL. This highlights both the severity of alterations in iron metabolism in ACLF, as well as the need to individualize cutoffs according to disease stage.

Reduced transferrin concentration in patients with cirrhosis can be attributed to impaired hepatic function, inflammation, alcohol consumption, or metabolic syndrome. In our study, transferrin correlates significantly with CRP but predicts survival independently of inflammation. In contrast, transferrin does not predict transplant-free survival independently of albumin. In patients with MELD-Na < 15, where this established score has poor discriminative accuracy, albumin remained the best predictor of survival in both cohorts. When alcohol and metabolic effects were excluded from the model, by selecting only patients with viral, genetic, cholestatic, and autoimmune etiology, transferrin was confirmed as a predictor of transplant-free survival independently of MELD-Na, CRP, and albumin. The finding that patients with fatty liver disease have significantly lower transferrin concentration confirms that alcohol and metabolic factors directly suppress transferrin synthesis. This effect could explain why albumin is a stronger predictor of survival than transferrin when also patients with fatty liver disease are included in the survival analysis.

Association studies cannot discern if altered serum iron parameters are a mere consequence or a driver of disease progression in patients with cirrhosis. Regardless of the exact hierarchy of events, excess iron will impair different immune effector functions and can induce ferropotosis—a recently identified form of programmed cell death triggered by iron. Toxic nontransferrin-bound iron species increase when plasma transferrin concentration decreases and are specifically taken up by hepatocytes. Accordingly, hepatic iron overload has been histologically reported in 32.4% of patients with end-stage liver disease. Impaired hepatocellular function has also been associated with decreased hepcidin production, which can lead to uncontrolled release of iron from cells. Reduced plasma iron binding capacity and increased iron release in cirrhosis could therefore promote hepatocellular iron toxicity in cirrhosis. The results from our study support the hypothesis that increasing iron binding capacity in plasma could improve survival in patients with cirrhosis. This can be achieved by administering apo-transferrin or hepcidin agonists, which are currently in clinical development.

In conclusion, our study shows that transferrin predicts transplant-free survival independently of MELD-Na score in unselected patients with cirrhosis. Regardless of etiology and cirrhosis stage, transferrin ≥ 180 mg/dL is associated with significantly better prognosis. More complex survival modeling in this large cohort shows that the prognostic value of transferrin is independent of inflammation. Albumin appears to be a stronger predictor of survival than transferrin in patients with ALD and NAFLD. The albumin-independent association of transferrin with survival in patients without fatty liver disease confirms that alcohol and metabolic factors represent an additional burden on iron metabolism and influence how serum iron parameters predict survival in patients with cirrhosis.

**REFERENCES**

1. Brown RS Jr, Lake JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 2005;5:203-204.
2. Habib S, Berk B, Chang CC, Dementis AJ, Fontes P, Dworochik I, et al. MELD and prediction of post-liver transplantation survival. Liver Transpl 2006;12:440-447.
3. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
4. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Soliman T, Steininger R, et al. Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int 2006;19:275-281.
5. Kim WR, Biggs SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-1026.
6. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13:1174-1180.
7. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343.
8. Weismuller TJ, Kirchner GI, Scherer MN, Negm AA, Schnitzbauer AA, Lehner F, et al. Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology 2011;54:2114-2124.
9. Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010;51:1683-1691.
10. Al-Freah MA, Kriese S, Foxton MR, Quaglia A, Bomford A, Heaton ND, et al. The association of pretransplant ferritin level
with waiting list and post-transplant survival. Does ferritin actually predict outcome? Transpl Int 2013;26:1070-1079.
11) Weissmüller TJ, Manns MP, Strassburg CP. Ferritin and liver allocation? Impact on mortality not only on the waiting list but also after orthotopic liver transplantation should be considered. Hepatology 2010;52:392-393.
12) Bruns T, Nuraldeen R, Mai M, Stengel S, Zimmermann HW, Yagmur E, et al. Low serum transferrin correlates with acute-on-chronic organ failure and indicates short-term mortality in decompensated cirrhosis. Liver Int 2017;37:232-241.
13) Maras JS, Maiwall R, Harsha HC, Das S, Hussain MS, Kumar C, et al. Dysregulated iron homeostasis is strongly associated with multigorgan failure and early mortality in acute-on-chronic liver failure. Hepatology 2015;61:1306-1320.
14) Bergmann OM, Mathahs MM, Broadhurst KA, Weydert JA, Wilkinson N, Howe JR, et al. Altered expression of iron regulatory genes in cirrhotic human livers: clues to the cause of hemosiderosis? Lab Invest 2008;88:1349-1357.
15) Macedo MF, de Sousa M. Transferrin and the transferrin receptor: of magic bullets and other concerns. Inflamm Allergy Drug Targets 2008;7:41-52.
16) Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999;13:273-279.
17) Moirand R, Mortaji AM, Loréal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-97.
18) Fletcher LM, Halliday JW, Powell LW. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. J Gastroenterol Hepatol 1999;14:202-214.
19) Whitfield JB, Zhu G, Heath AC, Powell LW, Martin NG. Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res 2001;25:1037-1045.
20) Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, et al. Does this patient with liver disease have cirrhosis? JAMA 2012;307:832-842.
21) Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
22) Finkenstedt A, Dorn L, Edlinger M, Prokop W, Risch L, Griesmacher A, et al. Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int 2012;32:1211-1216.
23) Tacke F, Nuraldeen R, Koch A, Strathmann K, Hutschenreuter G, Trautwein C, Strnad P. Iron parameters determine the prognosis of critically ill patients. Crit Care Med 2016;44:1049-1058.
24) Dixson SJ, Lemberg KM, Lamsprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060-1072.
25) Wang H, An P, Xie E, Wu Q, Fang X, Gao H, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology 2017;66:449-465.
26) Bradbury MW, Raja K, Ueda F. Contrasting uptakes of 59Fe into spleen, liver, kidney and some other soft tissues in normal and hypotransferrinaemic mice. Influence of an antibody against the transferrin receptor. Biochem Pharmacol 1994;47:969-974.
27) Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997;112:882-888.
28) Kaplan J, Craven C, Alexander J, Kushner J, Lamb J, Bernstein S. Regulation of the distribution of tissue iron. Lessons learned from the hypotransferrinemic mouse. Ann N Y Acad Sci 1988;526:124-135.
29) Liu J, Sun B, Yin H, Liu S. Hepcidin: a promising therapeutic target for iron disorders: a systematic review. Medicine (Baltimore) 2016;95:e3150.